{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:18:56Z","timestamp":1781713136977,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clgc.2019.05.023","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T10:48:57Z","timestamp":1558781337000},"page":"315-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6601-3726","authenticated-orcid":false,"given":"Gustavo","family":"Schvartsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre P.C.D.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee Z.","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.05.023_bib1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.023_bib2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.05.023_bib3","first-page":"530","article-title":"Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras","volume":"198","author":"Keskin","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.05.023_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.05.023_bib5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/hupa.2001.24984","article-title":"Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases","volume":"32","author":"Delahunt","year":"2001","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2019.05.023_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00000478-200404000-00002","article-title":"Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome","volume":"28","author":"Cheville","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2019.05.023_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jmoldx.2016.09.011","article-title":"A\u00a0targeted high-throughput next-generation sequencing panel for clinical screening of mutations, gene amplifications, and fusions in solid tumors","volume":"19","author":"Luthra","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clgc.2019.05.023_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.18632\/oncoscience.161","article-title":"Retrospective review of MET gene mutations","volume":"2","author":"Zenali","year":"2015","journal-title":"Oncoscience"},{"key":"10.1016\/j.clgc.2019.05.023_bib9","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.jtho.2016.11.624","article-title":"Characterization of MET-N375S as an activating mutation in squamous cell carcinoma of the lung: topic: driver genes in NSCLC, resistance, and other","volume":"12","author":"Kong","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clgc.2019.05.023_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/17843286.2016.1201614","article-title":"Abscopal effect in metastatic renal cell carcinoma","volume":"72","author":"Van de Walle","year":"2017","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.clgc.2019.05.023_bib11","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2015.07.008","article-title":"Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features","volume":"68","author":"Geynisman","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.05.023_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.clgc.2019.05.023_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clgc.2019.05.023_bib14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clgc.2019.05.023_bib15","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1002\/cncr.30937","article-title":"Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation","volume":"123","author":"Kawakami","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.05.023_bib16","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/j.clgc.2017.05.018","article-title":"Immune check point inhibition in sarcomatoid renal cell carcinoma: a new treatment paradigm","volume":"15","author":"Raychaudhuri","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.023_bib17","doi-asserted-by":"crossref","first-page":"e1127","DOI":"10.1016\/j.clgc.2017.05.028","article-title":"Rapid response to nivolumab in a patient with sarcomatoid transformation of chromophobe renal cell carcinoma","volume":"15","author":"Rouvinov","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.05.023_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2019.03.018","article-title":"Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes [e-pub ahead of print]","author":"Ged","year":"2019","journal-title":"Clin Genitourin Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319301612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319301612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:30:47Z","timestamp":1761564647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319301612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1558767319301612"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.05.023","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}